News

MK-3000, formally known as EYE103, is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wnt signaling pathway.

Prevent Blindness is planning a series of events and program partnerships leading up to World Sight Day on Oct. 10, 2024.

The one-time intravitreally delivered gene therapy is for the treatment of retinitis pigmentosa (RP).

This certification covers AI based regulatory requirements for the company's platform for AI imaging and diagnostic tools.

Data from this trial will be reported ahead of AAO 2024 in Chicago, Illinois.

The 4-year study is set to involve up to 20 patients and is a part of the Foundation's Uni-Rare natural history study.

InMed Pharmaceuticals has been issued 3 US patents, one of which is for an ocular drug delivery formulation for potential use in AMD.

The day will be held on October 10. It is coordinated by the International Agency for the Prevention of Blindness under the “Love Your Eyes” campaign banner, and is putting children at the center of the campaign.

Australian researchers have found that clinical registries may be an untapped font of information for artificial intelligence.

The product candidate is a modifier gene therapy for broad retinitis pigmentosa indication.

The Phase 1 trial is a multicenter, open-label, dose-escalation safety clinical trial, with 18 subjects, who each have received a single periocular injection of AIV007

In this study, the investigators retrospectively analyzed the incidence of metastasis in 8,034 patients with uveal melanoma over a 35-year period based on tumor size category.

Hannah Chiu, MD, FRCSC, highlights some of the early benefits of an AI-operated telephone call system for postoperative patient care.

These 4 women will feature in talks across the WIO Summer Symposium. Together they welcome all attendees to the 2024 meeting in Carlsbad, California.

The next step for the research likely will focus on determining whether blocking GSK3 can reverse existing AMD damage, potentially leading to new treatment options.

Nicole Bajic, MD, shared a bit about the skills labs at the Women in Ophthalmology Summer Symposium, the value that this meeting provides, and what she is looking forward to at this event.

Christina Y. Weng, MD, MBA discussed what attendees, both virtually and in-person, can expect from this year's Women in Ophthalmology Summer Symposium meeting in Carlsbad, California. The meeting will take place August 22-25, 2024.

The WIO Summer Symposium offers attendees a chance to network, build practice management skills, and plan to reach new goals and milestones in their career.

Going forward, the company will operate under the Ocuvex name, building on Visiox's commitment to disrupting the ophthalmic market through high-level collaboration with eye care professionals.

According to the company, the priority review voucher would be issued upon approval of OPGx-LCA5.

According to the company, the pre-clinical safety and efficacy studies of its product have yielded positive results in 3 internationally recognized labs in India, Singapore and the United States.

PAS-nomacopan is a long-acting bispecific inhibitor of C5 and leukotriene B4 for intravitreal treatment of geographic atrophy (GA).

The growing body of evidence that suggests that maintaining adequate levels of vitamin D may be beneficial for preventing and managing RVO.

In English and Spanish TV and radio spots, the public is urged to protect their vision from preventable blindness and vision loss by seeking care from a retina specialist at the first sign of retinal disease.

The Australian Society of Ophthalmologists hosted its inaugural Eye Surgery Showcase, where participants learned how ophthalmologists and the medical technology industry are working together to save the sight of Australians.

EC-104 is a novel intravitreal (IVT) corticosteroid implant with intended 6 months durable drug release for the treatment of DME.

The NIH-funded study finds lack of coverage, copays, restrictive policies barriers to vital eye care for adults.

The LIGHTHOUSE study a Phase I/II, open-label, dose-escalation and dose-expansion clinical trial is currently investigating the safety and tolerability of ASTN-201 for XLRS.